Kiniksa Pharmaceuticals International Plc Quick Ratio (KNSA) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)

Kiniksa Pharmaceuticals International Plc's Quick Ratio

KNSA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kiniksa Pharmaceuticals International Plc's Cash & cash equivalent grew by 13.05 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Kiniksa Pharmaceuticals International Plc's Quick Ratio to 2.99, Quick Ratio remained below Kiniksa Pharmaceuticals International Plc average.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Quick Ratio than Kiniksa Pharmaceuticals International Plc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 94, from total ranking in the fourth quarter 2025 at 585.

Explain Quick Ratio?
How much Cash & cash equivalents KNSA´s has?
What are KNSA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KNSA Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 61.01 % 38.33 % 28.8 % 39.79 % 51.48 %
Y / Y Cash & cash equivalent Change 74.44 % 69.96 % 57.34 % 40.7 % 25.66 %
Quick Ratio MRQ 2.99 2.98 2.85 2.61 2.76
KNSA's Total Ranking # 94 # 585 # 764 # 799 # 177
Seq. Current Liabilities Change 12.52 % 12.62 % 4.89 % 21.14 % -3.33 %
Seq. Cash & cash equivalent Change 13.05 % 17.6 % 14.4 % 14.7 % 10.14 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 27
Overall Market # 94


Quick Ratio Statistics
High Average Low
15.57 5.56 2.33
(Sep 30 2020)   (Sep 30 2024)




Financial Statements
Kiniksa Pharmaceuticals International Plc's Current Liabilities $ 157 Millions Visit KNSA's Balance sheet
Kiniksa Pharmaceuticals International Plc's Cash & cash equivalent $ 468 Millions Visit KNSA's Balance sheet
Source of KNSA's Sales Visit KNSA's Sales by Geography


Cumulative Kiniksa Pharmaceuticals International Plc's Quick Ratio

KNSA's Quick Ratio for the trailling 12 Months

KNSA Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 42.07 % 38.48 % 50.87 % 65.53 % 78.47 %
Y / Y Cash & cash equivalent TTM Growth 61.56 % 49.19 % 35.87 % 24.26 % 18.43 %
Quick Ratio TTM 2.87 2.81 2.67 2.53 2.52
Total Ranking TTM # 622 # 2409 # 2819 # 305 # 3135
Seq. Current Liabilities TTM Growth 12.42 % 8.78 % 6.71 % 8.87 % 9.58 %
Seq. Cash & cash equivalent TTM Growth 14.88 % 14.55 % 12.3 % 9.33 % 6.09 %

Quick ratio ranking by company, industry and sector >> Back to KNSA Financial Strength Comparisons >> Go to Compare KNSA Quick Ratio to its Competitors

On the trailing twelve months basis KNSA Cash & cash equivalent soared by 74.44 % in Q1 2026 year on year, faster than Current Liabilities, this led to increase in in Kiniksa Pharmaceuticals International Plc's Quick Ratio to 2.87, Quick Ratio remained below KNSA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Quick Ratio than Kiniksa Pharmaceuticals International Plc. While Quick Ratio overall ranking has improved so far to 622, from total ranking during the twelve months ending fourth quarter 2025 at 2409.

Explain Quick Ratio?
How much Cash & cash equivalents KNSA´s has?
What are KNSA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 33
Healthcare Sector # 90
Within the Market # 622


trailing twelve months Quick Ratio Statistics
High Average Low
11.84 5.06 2.52
(Dec 31 2020)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Corbus Pharmaceuticals Holdings Inc   8.16 $ 138.219  Millions$ 16.933  Millions
Biovie Inc   8.13 $ 13.099  Millions$ 1.611  Millions
Aardvark Therapeutics Inc   8.09 $ 91.200  Millions$ 11.268  Millions
Lite Strategy Inc   7.92 $ 7.544  Millions$ 0.952  Millions
Atea Pharmaceuticals Inc   7.82 $ 256.006  Millions$ 32.733  Millions
Bullfrog Ai Holdings Inc   7.79 $ 5.080  Millions$ 0.652  Millions
Moonlake Immunotherapeutics  7.76 $ 357.921  Millions$ 46.114  Millions
Korro Bio Inc   7.71 $ 113.970  Millions$ 14.787  Millions
Xenetic Biosciences Inc   7.67 $ 7.347  Millions$ 0.958  Millions
Mineralys Therapeutics Inc   7.66 $ 112.779  Millions$ 14.718  Millions
Centessa Pharmaceuticals Plc  7.56 $ 276.589  Millions$ 36.574  Millions
Adicet Bio Inc   7.52 $ 137.592  Millions$ 18.298  Millions
Cartesian Therapeutics Inc   7.44 $ 118.641  Millions$ 15.945  Millions
Q32 Bio Inc   7.36 $ 50.751  Millions$ 6.892  Millions
Ibio inc   7.32 $ 47.641  Millions$ 6.504  Millions
Anaptysbio Inc   7.24 $ 286.455  Millions$ 39.582  Millions
Avalo Therapeutics Inc   7.08 $ 82.140  Millions$ 11.599  Millions
Alx Oncology Holdings Inc  6.95 $ 140.324  Millions$ 20.178  Millions
Lyell Immunopharma Inc   6.88 $ 254.023  Millions$ 36.947  Millions
Zymeworks Inc   6.85 $ 244.282  Millions$ 35.649  Millions
Telomir Pharmaceuticals Inc   6.72 $ 5.561  Millions$ 0.827  Millions
Biohaven Ltd   6.68 $ 347.817  Millions$ 52.075  Millions
Silence Therapeutics Plc  6.63 $ 90.590  Millions$ 13.668  Millions
Dermata Therapeutics Inc   6.60 $ 6.945  Millions$ 1.053  Millions
Azitra Inc   6.49 $ 10.051  Millions$ 1.550  Millions
Sionna Therapeutics Inc   6.48 $ 63.324  Millions$ 9.776  Millions
Assembly Biosciences Inc   6.47 $ 226.601  Millions$ 34.997  Millions
Renovorx Inc   6.44 $ 12.362  Millions$ 1.920  Millions
Opus Genetics Inc   6.42 $ 59.959  Millions$ 9.340  Millions
Amarin Corp Plcuk  6.40 $ 308.023  Millions$ 48.153  Millions

Date modified: 2026-09-26T07:37:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.